argenx SE (NASDAQ:ARGX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of argenx SE (NASDAQ:ARGX) have earned a consensus rating of “Moderate Buy” from the nineteen ratings firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and sixteen have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $547.11.

ARGX has been the topic of several research analyst reports. Piper Sandler raised their price objective on shares of argenx from $595.00 to $600.00 and gave the stock an “overweight” rating in a research note on Thursday, August 31st. Jefferies Financial Group upped their price target on argenx from $605.00 to $628.00 in a report on Monday, October 2nd. Truist Financial reissued a “buy” rating and set a $570.00 price objective on shares of argenx in a report on Wednesday, November 1st. Scotiabank started coverage on argenx in a research note on Monday, July 31st. They issued a “sector perform” rating and a $516.00 target price for the company. Finally, Wells Fargo & Company lifted their price target on shares of argenx from $606.00 to $609.00 and gave the stock an “overweight” rating in a research note on Friday, July 28th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. TimesSquare Capital Management LLC raised its stake in argenx by 12.2% in the 3rd quarter. TimesSquare Capital Management LLC now owns 101,750 shares of the company’s stock valued at $50,023,000 after acquiring an additional 11,060 shares during the period. Creative Planning raised its stake in argenx by 55.7% during the third quarter. Creative Planning now owns 2,635 shares of the company’s stock worth $1,295,000 after acquiring an additional 943 shares in the last quarter. Townsquare Capital LLC lifted its holdings in shares of argenx by 96.6% in the third quarter. Townsquare Capital LLC now owns 3,442 shares of the company’s stock worth $1,692,000 after acquiring an additional 1,691 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of argenx by 5.6% during the third quarter. Royal Bank of Canada now owns 24,212 shares of the company’s stock valued at $11,902,000 after purchasing an additional 1,282 shares in the last quarter. Finally, Royal London Asset Management Ltd. acquired a new position in argenx in the 3rd quarter valued at approximately $23,468,000. 52.77% of the stock is owned by institutional investors and hedge funds.

argenx Price Performance

NASDAQ ARGX opened at $489.77 on Friday. The firm has a market capitalization of $28.94 billion, a PE ratio of -117.73 and a beta of 0.79. argenx has a 12 month low of $333.07 and a 12 month high of $550.76. The company’s 50 day simple moving average is $493.30 and its 200 day simple moving average is $460.93.

argenx (NASDAQ:ARGX) last issued its earnings results on Tuesday, October 31st. The company reported ($1.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.48) by $0.23. argenx had a negative return on equity of 12.40% and a negative net margin of 22.70%. The business had revenue of $339.84 million for the quarter, compared to analysts’ expectations of $310.06 million. During the same period in the previous year, the firm posted ($4.26) EPS. Sell-side analysts anticipate that argenx will post -4.76 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC.